Cerevance Media Center
Current News
November 30, 2022
Cerevance to Present Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases – Biology and Therapeutics Conference and Publication in Neuropharmacology
- Presentation highlights a novel target identified for Alzheimer’s disease using Cerevance’s proprietary NETSseq platform
- Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated positive results in human and mouse cell based and electrophysiology assays relevant to neuroinflammation in neurodegenerative disease
- Data has been concurrently published in the peer-reviewed journal, Neuropharmacology
August 9, 2022
Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
Cerevance today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.
April 19, 2022
Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
Cerevance today announced the appointment of Craig Thompson to chief executive officer. Mr. Thompson brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries to the company.
March 31, 2022
Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
Cerevance today announced the completion of its Phase 2 clinical trial of CVN424, the company’s first-in-class, once-a-day, orally-delivered compound in development for the treatment of Parkinson’s disease.
News Archive
September 23, 2024
Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024
Cerevance chief executive officer, Craig Thompson, will participate in a panel at the Fierce Biotech Summit, taking place in Boston, MA from September 30 – October 1, 2024.
June 18, 2024
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
Cerevance to deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disease caused by mutations in the ataxia-telangiectasia mutated gene, leading to progressive neurological issues. Using Cerevance’s NETSseq platform, RNA from purified cerebellar cell types of A-T and control donors was analyzed and subsequently revealed significant astrocyte gene expression changes related to inflammation and immune response.
October 10, 2023
Cerevance to Participate at the 3rd Annual Needham Biotech Private Company Forum. Company management will host one-on-one meetings during the conference.
October 4, 2023
Cerevance to Participate at the 2023 Life Sciences Private Company Showcase
October 2, 2023
Cerevance to Present at the 36th European College of Neuropsychopharmacology Congress
Events Archive
December 1, 2020